Bayesian modeling links residual cancer burden shifts to survival, helping neoadjuvant breast cancer trials and FDA approvals predict real benefit.
June 2026
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Behind the FDA Approval: Daraxonrasib Delivers in Pancreatic Cancer
2
FDA Grants Fast Track Designation to ADC Varseta-M for mCRC
3
White Blood Cell Count May Help Refine Risk Assessment in Polycythemia Vera
4
Strategies Shift Beyond Traditional Management of Immune Thrombocytopenia
5